MAP2K7 and melanoma: The survival of patients with stage IV melanoma has recently improved due to anti-PD-1 immunotherapies and BRAF/MEK combination targeted therapies, up to the recently reported 5-year overall survival (OS) rate of 52% with the combination ipilimumab/nivolumab (1–5).